U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula 2Cl.Zn
Molecular Weight 136.315
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Zinc chloride

SMILES

[Cl-].[Cl-].[Zn++]

InChI

InChIKey=JIAARYAFYJHUJI-UHFFFAOYSA-L
InChI=1S/2ClH.Zn/h2*1H;/q;;+2/p-2

HIDE SMILES / InChI
Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttp://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/https://www.google.com/patents/US3130034http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783https://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.t3db.ca/toxins/T3D0733http://www.hmdb.ca/metabolites/HMDB01303
Curator's Comment: description was created based on several sources, including https://www.drugs.com/dosage/zinc-sulfate.html | https://www.ncbi.nlm.nih.gov/pubmed/10721938 | https://www.drugbank.ca/drugs/DB01593 | https://www.ncbi.nlm.nih.gov/pubmed/17132019

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

CNS Activity

Originator

Smithson, R.
38
Curator's Comment: Centuries before zinc was recognized as a distinct element, zinc ores were used for making brass (a mixture of copper and zinc). A brass dating from between 1400-1000 BC has been found in Palestine. An alloy containing 87% zinc was found in prehistoric ruins in Transylvania. The smelting of zinc ores with copper was apparently discovered in Cyprus and was used later by the Romans. Metallic zinc was produced in the 13th century in India by reducing calamine (zinc carbonate, ZnCO3) with organic substances such as wool. The metal was rediscovered later in Europe. William Champion set up a zinc industry in Bristol (England) in the 1740s.

Approval Year

1921
1468
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Activator
1447
Activator
1447
Hydrolytic Enzyme
38
ultraviolet B-induced damage
38
Target ID: ultraviolet B-induced damage
Interacts
323
Activator
1447
Zinc transporter ZIP1
38
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Binding Agent
1076
Zinc transporter ZIP2
38
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Binding Agent
1076
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Basic research
Unknown

Approved Use

Unknown
Primary
Approved
8583
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

1955
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Secondary
Approved
8583
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

2012
Primary
Approved
8583
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

2006
Primary
Approved
8583
ZINC OXIDE

Approved Use

Unknown
Primary
Approved
8583
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
Phase III
665
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
Phase III
665
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
PubMed

PubMed

TitleDatePubMed
In vitro activity of zinc salts against human rhinoviruses.
1987 Apr
A medicated polycarboxylate cement to prevent complications in composite resin therapy.
1990 Jan
Quadrupolar perturbed 14N NMR in the structurally commensurate and incommensurate phases of ammonium tetrachlorozincate.
1991 Apr 1
Zinc inhibition of renin and the protease from human immunodeficiency virus type 1.
1991 Sep 10
Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds.
1994 Dec
Iron chelators as therapeutic agents against Pneumocystis carinii.
1994 May
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.
1995 Nov 13
Inhibition of HIV-1 infection by zinc group metal compounds.
1999 Sep
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.
1999 Spring
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age.
2004
Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium.
2004 Jul 16
Impact of the mother's zinc deficiency on the woman's and newborn's health status.
2005
Erythrocyte zinc content in critically ill patients.
2005
Zinc in attention-deficit/hyperactivity disorder.
2005 Aug
Increased plasma levels of zinc in obese adult females on a weight-loss program based on a hypocaloric balanced diet.
2005 Nov-Dec
Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder.
2005 Sep 1
Effects of zinc supplementation in patients with type 1 diabetes.
2005 Summer
Characterization and inhibition of SARS-coronavirus main protease.
2006
Zinc nutritional status of morbidly obese patients before and after Roux-en-Y gastric bypass: a preliminary report.
2006 Apr
Copper and zinc concentrations in serum of healthy Greek adults.
2006 Apr 15
Effect of end-stage renal disease and diabetes on zinc and copper status.
2006 Jul
Elevated cortical zinc in Alzheimer disease.
2006 Jul 11
The effect of Ramadan on maternal nutrition and composition of breast milk.
2006 Jun
Seminal plasma zinc concentration and alpha-glucosidase activity with respect to semen quality.
2006 May
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats.
2006 May
Zinc homeostasis in aging: two elusive faces of the same "metal".
2006 Summer
Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
2007 Nov
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing.
2010 Dec
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.
2010 Feb
Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells.
2010 Jan 12
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells.
2010 Jul
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway.
2010 Oct
ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53 and p38 pathways.
2011 Dec
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.
2011 Jul
Responses of human cells to ZnO nanoparticles: a gene transcription study.
2011 Nov
Zinc induces chemokine and inflammatory cytokine release from human promonocytes.
2011 Nov 30
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity.
2012 Feb
Aerosolized ZnO nanoparticles induce toxicity in alveolar type II epithelial cells at the air-liquid interface.
2012 Feb
Distinct immunomodulatory effects of a panel of nanomaterials in human dermal fibroblasts.
2012 May 5
Standard molar enthalpy of combustion and formation of quaternary ammonium tetrachlorozincate [n-CnH2n+1 N(CH3)3]2 ZnCl4.
2013 Dec
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.
2013 Jan
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation.
2013 Sep
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.
2014 Jul 1
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.
2014 May 16
ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice.
2014 Nov 4
Endoplasmic reticulum stress and oxidative stress are involved in ZnO nanoparticle-induced hepatotoxicity.
2015 Apr 2
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.
2015 Sep
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.
2016 Oct 1
Patents

Patents

04005147
106
04090844
38
04134847
38
04292237
38
04376079
39
04377675
40
04404196
40
04565693
38
04670586
38
04740363
38
04743435
42
04904401
38
04950702
42
05064815
38
05149745
38
05442047
38
05539121
38
05646324
38
05773011
38
05911978
38
06140331
38
06303833
38
06706904
38
07375243
38
07585885
44
07799339
38
07959530
39
08258190
38
20060128799
38
20060270867
38
20070213331
40
20070249787
39
20080274173
38
20090092554
38
20100048844
38
20100117110
38
20100324259
38
7632959
38
CN105567322
38
EP0119068A1
38
US1767667
38
US20070265374
38
US2522537
38
US2537262
38
US3248354
38
US3453072
38
US3790469
38
US6853140
38

Sample Use Guides

In Vivo Use Guide
single intravenous injection of 50 Units per kg
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:00:11 GMT 2025
Edited
by admin
on Mon Mar 31 18:00:11 GMT 2025
Record UNII
86Q357L16B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZINCUM MURIATICUM
HPUS  
Preferred Name English
Zinc chloride
EP   HSDB   II   INCI   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
INCI  
Official Name English
Zinc chloride [WHO-DD]
Common Name English
ZINC CHLORIDE [HSDB]
Common Name English
NSC-529648
Code English
ZINC CHLORIDE [EP IMPURITY]
Common Name English
ZINC CHLORIDE [MI]
Common Name English
ZINC CHLORIDE [EP MONOGRAPH]
Common Name English
ZINC CHLORIDE [USP MONOGRAPH]
Common Name English
ZINC CHLORIDE [ORANGE BOOK]
Common Name English
ZINC CHLORIDE [MART.]
Common Name English
ZINC CHLORIDE [JAN]
Common Name English
ZINCUM MURIATICUM [HPUS]
Common Name English
ZINC CHLORIDE [II]
Common Name English
Classification Tree Code System Code
WHO-VATC QB05XA12
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
WHO-ATC B05XA12
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
EPA PESTICIDE CODE 87801
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
Code System Code Type Description
CHEBI
49976
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY
RXCUI
39937
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY RxNorm
DRUG BANK
DB14533
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY
NCI_THESAURUS
C29865
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY
SMS_ID
100000090232
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY
NCI_THESAURUS
C1505
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
CONCEPT Dietary Supplement
EPA CompTox
DTXSID2035013
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY
ECHA (EC/EINECS)
231-592-0
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY
RS_ITEM_NUM
1724736
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY
DAILYMED
86Q357L16B
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY
CAS
7646-85-7
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY
FDA UNII
86Q357L16B
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY
DRUG CENTRAL
4344
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY
HSDB
1050
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY
MESH
C016837
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY
ChEMBL
CHEMBL1200679
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY
NSC
529648
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY
PUBCHEM
5727
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY
EVMPD
SUB12622MIG
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY
MERCK INDEX
m11601
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY Merck Index
WIKIPEDIA
ZINC CHLORIDE
Created by admin on Mon Mar 31 18:00:11 GMT 2025 , Edited by admin on Mon Mar 31 18:00:11 GMT 2025
PRIMARY
Related Record Type Details
Structure of ZINC CATION
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of ZINC CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966